Accantec Group Partners with Entimo AG to Expand Life Science Analytics
Accantec Group is enhancing its service portfolio by partnering with Entimo AG, integrating the latter's clinical trial analysis software. This move specifically strengthens its offerings for the pharmaceutical, medical technology, and biotechnology sectors.
Heidelberg-based accantec Group has expanded its service offerings through a new partnership with Berlin-based Entimo AG. The collaboration will see accantec's Life Science team offer Entimo's software solutions for the analysis of clinical trials.
Accantec, with existing expertise in SAS, JMP, and R technologies, focuses on serving companies within the pharmaceutical, medical technology, biotechnology, bioinformatics, and chemical industries. The new alliance with Entimo provides accantec's clients with software designed to streamline and standardize the analysis of preclinical and clinical drug development data.
"Entimo's solutions are modern and flexible, with an intuitive user interface and built-in support for validation, making them a valuable addition to our service portfolio," stated Dr. Peter Bewerunge, Head of Life Science at accantec Group. "The ability to integrate SAS and R servers in parallel positions Entimo at the forefront of current technology."
Entimo's Integrated Clinical Environment (entimICE) is a metadata-driven platform that enables the creation of standardized, reproducible analysis processes for clinical trial data. This supports companies in meeting stringent regulatory requirements and improving the reliability of study outcomes.
The partnership represents a significant step for accantec in providing comprehensive data analysis solutions for the Life Science sector. The companies plan to present their joint offerings at the PhUSE Annual Conference 2015 in Vienna this October.